Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study Medha Baranwal11 Nov 2024 9:15 PM ISTUSA: Recent research published in the journal Fertility and Sterility has highlighted the significant benefits of relugolix combination therapy (CT)...
Akums Drugs and Pharmaceuticals Gets CDSCO Panel Nod To study Norethindrone, Estradiol, Relugolix FDC Dr. Divya Colin30 July 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug...
Alkem Laboratories Gets CDSCO Panel Nod To Manufacture Market Relugolix Tablets 120mg Dr. Divya Colin13 May 2024 6:00 PM ISTNew Delhi: Alekm Laboratories has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Sun Pharmaceutical Industries Gets CDSCO Panel Nod to Study FDC of Relugolix, Estradiol, Norethindrone Acetate Dr. Divya Colin8 April 2024 6:00 PM ISTNew Delhi: Rejecting for clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation...
Relugolix Rapidly Achieves Sustained Castration in Prostate Cancer Patients Undergoing Radiotherapy: Study Dr Riya Dave3 April 2024 10:30 PM ISTProstate cancer remains one of the most prevalent cancers in men worldwide, often requiring a multimodal treatment approach for optimal management....
No safety data available, Conduct Phase-III CT: CDSCO Panel Tells Akums on Norethindrone, Estradiol, Relugolix film-coated tablet Dr. Divya Colin12 Jan 2024 6:00 PM ISTNew Delhi: Citing that there is no safety and efficacy data, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Conduct Phase III CT: CDSCO Panel Tells Sun Pharma on FDC Relugolix plus Estradiol plus Norethindrone Acetate Tablets Dr. Divya Colin10 Jan 2024 6:00 PM ISTNew Delhi: Citing that there is no safety and efficacy data on Indian population, the Subject Expert Committee (SEC) functional under the Central Drug...
Justify inter-subject variability in BE study data: CDSCO Panel Tells Alkem on anticancer drug Relugolix Dr. Divya Colin7 Jan 2024 5:30 PM ISTNew Delhi: Reviewing the bioequivalence (BE) study report of the anti-cancer drug Relugolix presented by the drug major Alkem Laboratories, the...
Zydus Lifesciences gets CDSCO panel nod to manufacture, market Relugolix Tablets Dr. Divya Colin29 July 2023 6:00 PM ISTNew Delhi: Noting an unmet medical need in the country, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Submit safety and efficacy data: CDSCO panel Tells Zydus on Anticancer Drug Relugolix Dr. Divya Colin18 Jun 2023 10:00 AM ISTNew Delhi: In response to the drug major Zydus's proposal for the manufacture and marketing of the drug Relugolix 120 mg tablets, the Subject Expert...
Local CT waiver will be considered after submission of BE study result: CDSCO panel tells Synokem on Relugolix Dr. Divya Colin2 May 2023 6:00 PM ISTNew Delhi: Granting approval to conduct the bioequivalence study of Relugolix, an oral GnRH receptor antagonist for androgen deprivation therapy in...
Zydus Gets CDSCO panel Nod for BE Study Of Antineoplastic Drug Relugolix Dr. Divya Colin2 Jan 2023 5:30 PM ISTNew Delhi: In response to the drug major Zydus proposal for manufacture and market of anticancer drug Relugolix Tablets 120mg along with...
